Navigation Links
Omeros Reports Outcome of Phase 3 Trials of OMS103HP
Date:3/31/2011

Company's expectation that it will provide additional information on its plans for OMS103HP and that Omeros may have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 15, 2011. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
2. Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
3. Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
4. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
5. Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
6. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
7. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
8. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
11. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ) ... Monday, December 8, 2014 at 9:00 a.m. Eastern Time to ... th American Society of Hematology Annual Meeting and Exposition.  ... by dialing 877-443-5662 or access the webcast at www.isispharm.com ... time at the same address. ABOUT ISIS ...
(Date:11/18/2014)... 18, 2014  Renova Therapeutics, a biopharmaceutical company ... and other chronic diseases, announced that Daniel ... The company also completed its third round of ... board member brings decades of life science experience ... executive with more than 30 years of experience ...
(Date:11/17/2014)... STAAR Surgical Company (NASDAQ: STAA ... lenses and delivery systems for the eye, today announced ... Medical Technology & Diagnostics Forum in New ... Thursday, November 20 at 12:30 p.m. PT/3:30 p.m. ET. ... of the Company,s current business trends, financial results, and ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-FXI Rx Data Presented at the ASH Annual Meeting 3Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 2Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 3STAAR Surgical To Present At The Canaccord Genuity 2014 Medical Technology & Diagnostics Forum 2
(Date:11/18/2014)... HealthDay Reporter MONDAY, Nov. 17, ... to extremely low levels with a combination drug appears ... patients with clogged arteries, a new study found. ... Vytorin, a drug that combines a cholesterol-lowering statin called ... investigator Dr. Christopher Cannon, a cardiologist at Brigham and ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... Hills, CA (PRWEB) November 18, 2014 ... and workflow solutions, announced today their Gold sponsorship of ... November 19th through Friday, November 21st at the Fargo, ... event offering targeted Microsoft Dynamics GP training sessions and ... the Microsoft campus is an excellent way for users ...
(Date:11/18/2014)... Recently, Wigsbuy has introduced its newest collection of ... greatly discounted prices now, up to 85% off. , Wigsbuy ... products, offering many real and synthetic hair products. In order ... uses high quality materials to make its hair wigs, which ... , “We are offering a full line of human ...
(Date:11/18/2014)... Thompson HealthDay Reporter , MONDAY, ... patients can safely take aspirin combined with a blood-thinning medication, ... a patient,s risk of early death, according to a new ... Heart Association in Chicago. The report was also published online ... data from more than a dozen clinical trials revealed no ...
Breaking Medicine News(10 mins):Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 2Health News:Cholesterol Drug Vytorin Linked to Reduced Heart Attack Risk 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 2Health News:Altec Joins the 2014 Great Plains User Conference (GPUC) as a Gold Sponsor, Demonstrating the Capabilities of Certified for Microsoft Dynamics Product doc-link 3Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
... Sudden cardiac,arrest is a leading cause of death ... condition, it is imperative that every school develop ... they need to respond,effectively to children and adults ... perform CPR and use an automated external defibrillator,(AED) ...
... Jones addressed the issue of health disparities during a,Ways ... part are,as follows., "Mr. Chairman, I am appreciative ... disparities as we continue to move forward with,health reform ... not just to my district, but to,districts across the ...
... on the Impact of ... Technology in Healthcare, PLANO, Texas, June 10 ... President, International Healthcare Guest: ... Humana, Perot Systems continues its series of ...
... drug approved for osteoporosis prevention and treatment has provided ... a breast cancer preventative for certain cancers. Women ... develop invasive, estrogen-receptor (ER) positive breast cancer compared with ... results of the randomized controlled trial will be published ...
... , , TUESDAY, June 10 (HealthDay News) -- Regardless of the ... women, and smoking increases any adult,s risk of death just ... according to new risk of death charts. , The charts, ... the Journal of the National Cancer Institute show ...
... Maine, June 10 Sen. Olympia Snowe,(R-ME), member ... Medicare,bill -- S.3101 -- that includes pharmacy-related provisions ... drug claims and delay the,implementation of Medicaid reimbursement ... RPh, owner of Waltz Pharmacy Inc. in,Camden, ME ...
Cached Medicine News:Health News:Statement of Robert O'Connor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act 2Health News:Tubbs Jones Addresses Health Disparities Issue During Hearing 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 3Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 2Health News:Anti-estrogen drug therapy reduces risk of invasive breast cancer in older women 3Health News:Researchers Update Risk-of-Death Charts 2Health News:Maine Community Pharmacy Owner Thanks Sen. Snowe for Supporting Inclusion of Common-Sense Reimbursement Provisions in Medicare Bill 2
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish....
... designed with thinner, long jaws to ... through a tunnel or clear corneal ... lens securely, but will not damage ... enough to allow the lens to ...
Titanium. Designed to easily fold the hydroview lens. Will also fold many styles of soft intraocular lenses. Unique cross-action design facilitates folding of the lens....
Angled 45 degree shafts. 7 mm from tip to bend with grooved 2 mm platform for grasping lens haptic. Serrated McPherson style handle with dull finish....
Medicine Products: